A Phase 2 interventional study of LY3337641 and Placebo in Rheumatoid Arthritis, sponsored by Eli Lilly and Company. Terminated at 71 sites in 13 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-10-09.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Eli Lilly and Company.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 13 in phase 2, and was the 27th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company are open now, in 5 countries. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Australia, China, Japan
Ages 18–55 · Healthy volunteers
Eli Lilly and Company · Sites in United States, Germany
Ages 18–75 · Healthy volunteers
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 14 · Phase 3 11 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 286 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 164 across the 35 interventional studies. Of the 33 that completed or were terminated, 30 (91%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Arthritis, Rheumatoid by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and effectiveness of LY3337641 in adults with rheumatoid arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have at least 1 of the following:
Have active RA, defined as:
Exclusion Criteria:
Have received any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Given once a day for 4 weeks.
Drug: LY3337641
Given once a day for 4 weeks.
Drug: LY3337641
Given once a day for 4 weeks.
Drug: LY3337641
Given once a day for 4 weeks.
Drug: Placebo
Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
Drug: LY3337641
Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
Drug: LY3337641
Given once a day for 12 weeks and an additional 52 weeks for Long-term extension (LTE) period.
Drug: LY3337641
Given once a day for 12 weeks.
Drug: Placebo
Administered orally
Administered orally
Number of Participants With One or More Treatment-Emergent Adverse Events (TEAEs) or Adverse Events of Special Interest (AESIs) or Any Serious AEs (SAEs) in Part A
TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. Skin Rash was the only event that was considered an AESI. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of SAEs and other non-serious AEs, regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.
Time frame: Up to 6 Weeks
Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response in Part B
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient's Global Assessment of Arthritis Pain using visual analog scale (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and /or participants who discontinue study or drug before analysis timepoint are deemed non-responders.
Time frame: Week 12
Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response in Part B
ACR50 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR50 Responder" is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient's Global Assessment of Arthritis Pain using VAS, HAQ-DI and hsCRP. Participants with missing responses and/or participants who discontinue study or drug before analysis timepoint are deemed non-responders.
Time frame: Week 12
Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response in Part B
ACR70 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR70 Responder" is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient's Global Assessment of Arthritis Pain using VAS, HAQ-DI and hsCRP. Participants with missing responses and/or participants who discontinue study or drug before analysis timepoint are deemed non-responders.
Time frame: Week 12
Change From Baseline in the Disease Activity Score (DAS) 28-high-sensitivity C-reactive Protein (hsCRP) in Part B
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using VAS. DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Baseline, Week 12
Percentage of Participants Who Achieve Low Disease Activity Using DAS28-hsCRP in Part B
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using VAS. DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
Time frame: Week 12
Percentage of Participants Who Achieve Clinical Remission Using DAS28-hsCRP in Part B
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (participant global VAS). DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Clinical remission is defined as DAS28-hsCRP \<2.6.
Time frame: Week 12
Pharmacokinetics (PK): Clearance Parameter of LY3337641
Apparent total body clearance of drug after oral administration based on population PK analysis was evaluated. As prespecified per protocol, an overall population estimate of clearance is generated and data from Part A and B were combined for the analysis. The sparse data was then analyzed using population PK methods in Non linear Mixed Effects Model (NONMEM) to generate an overall population estimate of clearance.
Time frame: Part A: Weeks 1, 2, and 4, Day 1 (0.5 to 2 hours postdose); Part B: Weeks 2, 4, 8, and 12, Day 1 (0.5 to 2 hours postdose)
| Milestone | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|---|---|---|---|
| Started | 9 | 9 | 10 | 8 | 62 | 63 | 62 | 63 |
| Received at least 1dose of study drug | 9 | 9 | 10 | 8 | 62 | 63 | 62 | 63 |
| Completed | 9 | 9 | 9 | 8 | 46 | 49 | 46 | 48 |
| Not completed | 0 | 0 | 1 | 0 | 16 | 14 | 16 | 15 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 2 | 4 | 1 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 2 | 1 | 3 | 2 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 7 | 6 | 7 | 7 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Site terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 2 | 1 | 2 | 4 |
| Milestone | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 61 | 58 | 61 |
| Placebo re-randomized in lte | 0 | 0 | 0 | 0 | 0 | 14 | 14 | 14 |
| Completed | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 60 | 58 | 61 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 3 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 0 | 0 | 0 | 0 | 52 | 51 | 51 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 3 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 3 | 4 | 3 |
TEAEs are any untoward medical occurrence that either occurs or worsens at any time after treatment baseline, and in the opinion of the investigators is possibly related to study drug. Skin Rash was the only event that was considered an AESI. A serious AE is defined as an event that results in death, initial or prolonged hospitalization, is life-threatening, leads to persistent or significant disability/incapacity, is associated with congenital anomaly/birth defect, or is considered significant by the investigator for any other reason. A summary of SAEs and other non-serious AEs, regardless of whether or not they were possibly related to study drug, is located in the Reported Adverse Event section.
| Participants | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 |
|---|---|---|---|---|
| TEAEs | 3 | 1 | 6 | 2 |
| AESIs | 0 | 0 | 0 | 0 |
| SAEs | 0 | 0 | 0 | 0 |
ACR20 Responder Index is a composite of clinical, laboratory, and functional measures in rheumatoid arthritis (RA). "ACR20 Responder" is a participant who has at least 20% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient's Global Assessment of Arthritis Pain using visual analog scale (VAS), Health Assessment Questionnaire - Disability Index (HAQ-DI) and high-sensitivity C-reactive protein (hsCRP). Participants with missing responses and /or participants who discontinue study or drug before analysis timepoint are deemed non-responders.
| Percentage of Participants | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response in Part B | 48.1 (34.8 to 61.5) | 55.4 (42.3 to 68.4) | 44.2 (30.7 to 57.7) | 50.9 (37.7 to 64.1) |
ACR50 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR50 Responder" is a participant who has at least 50% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient's Global Assessment of Arthritis Pain using VAS, HAQ-DI and hsCRP. Participants with missing responses and/or participants who discontinue study or drug before analysis timepoint are deemed non-responders.
| Percentage of Participants | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response in Part B | 27.8 (15.8 to 39.7) | 25.0 (13.7 to 36.3) | 15.4 (5.6 to 25.2) | 29.1 (17.1 to 41.1) |
ACR70 Responder Index is composite of clinical, laboratory, and functional measures in RA. "ACR70 Responder" is a participant who has at least 70% improvement in both tender and swollen joint counts and in at least 3 of the following 5 criteria: Physician's Global Assessment of Disease Activity, Patient's Global Assessment of Disease Activity, Patient's Global Assessment of Arthritis Pain using VAS, HAQ-DI and hsCRP. Participants with missing responses and/or participants who discontinue study or drug before analysis timepoint are deemed non-responders.
| Percentage of Participants | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|
| Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response in Part B | 16.7 (6.7 to 26.6) | 8.9 (1.5 to 16.4) | 1.9 (0.0 to 5.7) | 16.4 (6.6 to 26.1) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using VAS. DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
| units on a scale | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|
| Change From Baseline in the Disease Activity Score (DAS) 28-high-sensitivity C-reactive Protein (hsCRP) in Part B | -1.62 ± 1.447 | -1.55 ± 1.182 | -1.24 ± 1.146 | -1.80 ± 1.453 |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using VAS. DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Scores ranged 1.0-9.4, where lower scores indicated less disease activity.
| Percentage of Participants | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|
| Percentage of Participants Who Achieve Low Disease Activity Using DAS28-hsCRP in Part B | 27.8 (15.8 to 39.7) | 32.1 (19.9 to 44.4) | 21.2 (10.1 to 32.3) | 29.1 (17.1 to 41.1) |
Disease Activity Score (DAS) modified to include 28 joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), C-reactive protein (CRP) (milligrams per liter), and Patient's Global Assessment of Disease Activity using visual analog scale (VAS) (participant global VAS). DAS28 was calculated using following formula: DAS28-CRP=0.56\*square root (sqrt)(TJC28)+0.28\*sqrt(SJC28)+0.36\*natural log(CRP+1)+0.014\*Patient's Global VAS+0.96. Clinical remission is defined as DAS28-hsCRP \<2.6.
| Percentage of Participants | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 |
|---|---|---|---|---|
| Percentage of Participants Who Achieve Clinical Remission Using DAS28-hsCRP in Part B | 20.4 (9.6 to 31.1) | 19.6 (9.2 to 30.0) | 7.7 (0.4 to 14.9) | 25.5 (13.9 to 37.0) |
Apparent total body clearance of drug after oral administration based on population PK analysis was evaluated. As prespecified per protocol, an overall population estimate of clearance is generated and data from Part A and B were combined for the analysis. The sparse data was then analyzed using population PK methods in Non linear Mixed Effects Model (NONMEM) to generate an overall population estimate of clearance.
| Liter per hour (L/hr) | LY3337641 |
|---|---|
| Pharmacokinetics (PK): Clearance Parameter of LY3337641 | 29.1 ± 5.9 |
Collected over Up to 88 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Placebo | 0/9 (0%) | 0/9 (0%) | 3/9 (33.3%) |
| Part A: 5 mg LY3337641 | 0/9 (0%) | 0/9 (0%) | 1/9 (11.1%) |
| Part A: 10 mg LY3337641 | 0/10 (0%) | 0/10 (0%) | 6/10 (60%) |
| Part A: 30 mg LY3337641 | 0/8 (0%) | 0/8 (0%) | 2/8 (25%) |
| Part B: Placebo | 0/62 (0%) | 2/62 (3.2%) | 7/62 (11.3%) |
| Part B: 5 mg LY3337641 | 0/63 (0%) | 0/63 (0%) | 10/63 (15.9%) |
| Part B: 10 mg LY3337641 | 0/62 (0%) | 0/62 (0%) | 12/62 (19.4%) |
| Part B: 30 mg LY3337641 | 1/63 (1.6%) | 3/63 (4.8%) | 19/63 (30.2%) |
| Long-Term Extension: 5 mg LY3337641 | 0/61 (0%) | 1/61 (1.6%) | 11/61 (18%) |
| Long-Term Extension: 10 mg LY3337641 | 0/58 (0%) | 3/58 (5.2%) | 12/58 (20.7%) |
| Long-Term Extension: 30 mg LY3337641 | 0/61 (0%) | 1/61 (1.6%) | 10/61 (16.4%) |
| Event | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Long-Term Extension: 5 mg LY3337641 | Long-Term Extension: 10 mg LY3337641 | Long-Term Extension: 30 mg LY3337641 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ankle fractureInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 1/58 | 0/61 |
| Hand fractureInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 1/58 | 0/61 |
| Patella fractureInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 1/58 | 0/61 |
| Pubis fractureInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 1/58 | 0/61 |
| Wrist fractureInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 1/58 | 0/61 |
| NephrolithiasisRenal and urinary disorders | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 1/58 | 0/61 |
| PneumoniaInfections and infestations | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 0/58 | 1/61 |
| Alanine aminotransferase increasedInvestigations | 0/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 1/61 | 0/58 | 0/61 |
| Cholecystitis acuteHepatobiliary disorders | 0/9 | 0/9 | 0/10 | 0/8 | 1/62 | 0/63 | 0/62 | 0/63 | 0/61 | 0/58 | 0/61 |
| Joint dislocationInjury, poisoning and procedural complications | 0/9 | 0/9 | 0/10 | 0/8 | 1/62 | 0/63 | 0/62 | 0/63 | 0/61 | 0/58 | 0/61 |
| Event | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Long-Term Extension: 5 mg LY3337641 | Long-Term Extension: 10 mg LY3337641 | Long-Term Extension: 30 mg LY3337641 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 0/9 | 0/9 | 2/10 | 1/8 | 0/62 | 1/63 | 1/62 | 1/63 | 0/61 | 0/58 | 0/61 |
| ConstipationGastrointestinal disorders | 0/9 | 0/9 | 0/10 | 1/8 | 0/62 | 0/63 | 1/62 | 0/63 | 0/61 | 0/58 | 0/61 |
| BronchitisInfections and infestations | 0/9 | 0/9 | 0/10 | 1/8 | 0/62 | 0/63 | 0/62 | 2/63 | 1/61 | 3/58 | 1/61 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/1 | 0/1 | 0/1 | 0/3 | 1/8 | 0/10 | 0/6 | 0/10 | 0/9 | 0/4 | 0/10 |
| DiarrhoeaGastrointestinal disorders | 1/9 | 0/9 | 0/10 | 0/8 | 0/62 | 1/63 | 0/62 | 2/63 | 0/61 | 0/58 | 0/61 |
| Dry mouthGastrointestinal disorders | 0/9 | 1/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 0/58 | 0/61 |
| PharyngitisInfections and infestations | 1/9 | 0/9 | 0/10 | 0/8 | 2/62 | 0/63 | 1/62 | 3/63 | 0/61 | 2/58 | 1/61 |
| SinusitisInfections and infestations | 1/9 | 0/9 | 0/10 | 0/8 | 0/62 | 1/63 | 1/62 | 1/63 | 0/61 | 2/58 | 2/61 |
| HypokalaemiaMetabolism and nutrition disorders | 1/9 | 0/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 2/63 | 0/61 | 1/58 | 0/61 |
| OsteopeniaMusculoskeletal and connective tissue disorders | 0/9 | 1/9 | 0/10 | 0/8 | 0/62 | 0/63 | 0/62 | 0/63 | 0/61 | 0/58 | 0/61 |
All randomized participants who received at least 1 dose of the study drug.
| Age, Continuous(years) | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 54.3 ± 11.43 | 54.0 ± 11.75 | 56.9 ± 6.44 | 51.9 ± 5.72 | 50.5 ± 8.75 | 50.1 ± 9.20 | 51.7 ± 9.36 | 51.9 ± 8.91 | 51.5 ± 9.09 |
| Sex: Female, Male(Participants) | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 8 | 8 | 9 | 5 | 54 | 53 | 56 | 53 | 246 |
| Male | 1 | 1 | 1 | 3 | 8 | 10 | 6 | 10 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 3 | 2 | 34 | 26 | 23 | 21 | 116 |
| Not Hispanic or Latino | 5 | 6 | 7 | 6 | 24 | 29 | 26 | 23 | 126 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 4 | 8 | 13 | 19 | 44 |
| Race (NIH/OMB)(Participants) | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Total |
|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 6 |
| Asian | 0 | 0 | 0 | 0 | 7 | 14 | 9 | 10 | 40 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 0 | 1 | 1 | 2 | 2 | 2 | 10 |
| White | 6 | 7 | 9 | 7 | 53 | 46 | 50 | 51 | 229 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A: Placebo | Part A: 5 mg LY3337641 | Part A: 10 mg LY3337641 | Part A: 30 mg LY3337641 | Part B: Placebo | Part B: 5 mg LY3337641 | Part B: 10 mg LY3337641 | Part B: 30 mg LY3337641 | Total |
|---|---|---|---|---|---|---|---|---|---|
| Puerto Rico | 0 | 0 | 0 | 0 | 4 | 2 | 3 | 5 | 14 |
| Argentina | 0 | 0 | 0 | 0 | 15 | 13 | 15 | 14 | 57 |
| United States | 6 | 6 | 6 | 7 | 12 | 13 | 15 | 6 | 71 |
| Japan | 0 | 0 | 0 | 0 | 6 | 6 | 6 | 7 | 25 |
| Spain | 0 | 0 | 0 | 0 | 1 | 3 | 3 | 6 | 13 |
| South Korea | 0 | 0 | 0 | 0 | 0 | 5 | 0 | 3 | 8 |
| Austria | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 |
| Poland | 0 | 0 | 2 | 1 | 9 | 9 | 4 | 7 | 32 |
| Italy | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 5 | 10 |
| Mexico | 3 | 3 | 2 | 0 | 10 | 6 | 7 | 4 | 35 |
| South Africa | 0 | 0 | 0 | 0 | 2 | 3 | 5 | 3 | 13 |
| Slovakia | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 |
| Australia | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · www.clinicalstudydatarequest.com
Ran from Aug 2016 to primary completion in Apr 2018, 20 months.
Results were first posted in Oct 2019, 1 year 5 months after primary completion. A results delay was requested in Apr 2019.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Poseltinib